Aurobindo Recalls MARBETA L KIT Vials Due to Particulate Matter
Aurobindo Pharma USA Inc. is recalling 88,600 vials of MARBETA L KIT because one vial was found to contain a hair.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The agency classification is FDA Class I, which mandates a minimum severity score of 4 per the rubric.
Plain-English summary
Aurobindo Pharma USA Inc. is recalling 88,600 vials of MARBETA L KIT (Lot CLC180117, Exp. June 2021). The recall was initiated because one vial was found to contain a hair, which constitutes the presence of particulate matter.
The affected product is Lidocaine HCl Injection, USP 1 % 50 mg/5 mL (10 mg/mL), 5mL vial. The product is being held at distributor sites in Mexico, Asheboro, NC, Charlotte, NC, and Santa Teresa, NM, and has not been further distributed in the U.S. market.
Consumers and healthcare providers should check their inventory for this specific lot number and expiration date. If the product is found, it should be quarantined and not used.
The recalled product
- Product
- MARBETA L KIT (BETAMETHASONE SODIUM PHOSPHATE, BETAMETHASONE ACETATE, LIDOCAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE, POVIDINE IODINE, ISOPROPYL ALCOHOL)
- Brand
- MARBETA L KIT
- Manufacturer
- Aurobindo Pharma USA Inc.
- Category
- Drug — Injection
- Affected units
- 88,600
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: CLC180117
- Exp. June 2021
Distribution
Distribution scope not specified by the agency.
Related recalls
Same manufacturer · Aurobindo Pharma USA Inc.
See all →- ModerateDicyclomine Hydrochloride Capsules Recalled for Empty Capsules
FDA (Drugs) · 2026-08-12
- ModerateAmazon Basic Care Acetaminophen 325 mg Tablets Recalled Due to Discoloration
FDA (Drugs) · 2025-06-25
- HighPrescription drug recall: Aurobindo Nebivolol tablets contain excess nitrosamine impurity
FDA (Drugs) · 2024-12-25
- HighCinacalcet Tablets Recalled for N-Nitroso Impurity Exceeding FDA Safety Limit
FDA (Drugs) · 2024-12-11
- HighPrescription Cinacalcet Tablets Recalled for N-Nitroso Impurity
FDA (Drugs) · 2024-12-11
Same hazard · particulate matter
See all →- SevereACTHAR Gel Recalled for Presence of Glass and Stopper Particulate Matter
FDA (Drugs) · 2026-09-02
- SevereB. Braun Recalls Lactated Ringer's Injection Due to Particulate Matter
FDA (Drugs) · 2026-09-02
- CriticalAmerican Regent Recalls Papaverine Hydrochloride Injection Due to Particulate Matter
FDA (Drugs) · 2026-08-26
- SevereAmerican Regent Recalls Nitroglycerin Injection Due to Particulate Matter
FDA (Drugs) · 2026-08-26
- SevereAmerican Regent Recalls Cyanocobalamin Injections Due to Particulate Matter
FDA (Drugs) · 2026-08-26